Im Neuenheimer Feld 584
Phone: +49 (0)6221 1370 810
Fax: +49 (0)6221 1370 829
Gene Bridges GmbH is a self-financed biotechnology company pioneering “recombineering”, a scientific approach that allows site-specific and size-independent cloning/DNA modification. The Company’s Red/ET™ Recombination technology is a patent-protected recombineering technology that enables researchers the freedom to design and experiment in transgenics, E.coli chromosome modification and many other areas of genetic modification. The technology is a “copy and paste” cloning technology where the DNA of interest can easily be “copied and pasted” in or out of a vector or chromosome. Red/ET™ is the fastest and most accurate way to clone DNA and has been substantially validated in scores of peer-reviewed scientific publications.
Recombineering is a scientific approach that allows site-specific and size-independent cloning/DNA modification. Recombineering has a wide breadth of applications across transgenic pharma and biotech applications, biofuels, fine chemicals and food technology. With Red/ET™, DNA modification can be achieved regardless of restriction sites, giving scientists greater freedom to design experiments. Using Red/ET™ Recombination, the process from identifying DNA sequence to obtaining the functional construct takes weeks rather than months by conventional methods.
Commercial licenses are readily available to use the technology and Gene Bridges provides recombineering services and also ready-to-use recombineering kits for academic research. The Company is privately held and was founded in 2000 as spin-off from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. The company also maintains research facilities in Dresden. Further information on Gene Bridges can be found at www.genebridges.com